Under the alliance agreement, Sanofi Pasteur will have access to antigens identified by Institut Pasteur derived from plasmodium falciparum, the parasite responsible for the most deadly malaria infections. Sanofi Pasteur intends to use these antigens to develop a safe and efficacious candidate vaccine against malaria.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur is committed to making malaria a vaccine-preventable disease, ultimately relieving affected populations from this scourge. This agreement with Institut Pasteur underlines the company’s historical involvement in public-private partnerships with renowned institutions to help improve public health.”
Alice Dautry, president of Institut Pasteur, added: “Teaming with Sanofi Pasteur, a long-standing partner of the institute, increases the potential to reach the shared goal of a malaria vaccine. Through this agreement, Institut Pasteur and Sanofi Pasteur reinforce their collaboration to benefit public health.”